216 related articles for article (PubMed ID: 38095773)
21. Combining methionine-PET and MRI fluid-attenuated inversion-recovery mismatch to determine glioma molecular subtype.
Ohmura K; Kumagai N; Kumagai M; Ikegame Y; Shinoda J; Yano H; Muragaki Y; Iwama T
J Neuroimaging; 2023; 33(4):652-660. PubMed ID: 37158779
[TBL] [Abstract][Full Text] [Related]
22. Magnetic resonance imaging criteria for prediction of isocitrate dehydrogenase (IDH) mutation status in patients with grade II-III astrocytoma and oligodendroglioma.
Çelik S; Öven BB; Demir MK; Yılmaz EÇ; Kanan D; Özdamarlar U; Emirzeoglu L; Yapıcıer Ö; Kılıç T
Clin Neurol Neurosurg; 2021 Aug; 207():106745. PubMed ID: 34146841
[TBL] [Abstract][Full Text] [Related]
23. World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas: A Review.
Berger TR; Wen PY; Lang-Orsini M; Chukwueke UN
JAMA Oncol; 2022 Oct; 8(10):1493-1501. PubMed ID: 36006639
[TBL] [Abstract][Full Text] [Related]
24. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
[TBL] [Abstract][Full Text] [Related]
25. Integration of dynamic parameters in the analysis of
Ginet M; Zaragori T; Marie PY; Roch V; Gauchotte G; Rech F; Blonski M; Lamiral Z; Taillandier L; Imbert L; Verger A
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1381-1390. PubMed ID: 31529264
[TBL] [Abstract][Full Text] [Related]
26. [PET/CT with 11C-methionine in assessment of brain glioma metabolism].
Vikhrova NB; Kalaeva DB; Tyurina AN; Belyaev AY; Danilov GV; Pronin IN
Zh Vopr Neirokhir Im N N Burdenko; 2024; 88(1):63-69. PubMed ID: 38334732
[TBL] [Abstract][Full Text] [Related]
27. Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic
Vettermann F; Suchorska B; Unterrainer M; Nelwan D; Forbrig R; Ruf V; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2581-2589. PubMed ID: 31410540
[TBL] [Abstract][Full Text] [Related]
28.
Maurer GD; Brucker DP; Stoffels G; Filipski K; Filss CP; Mottaghy FM; Galldiks N; Steinbach JP; Hattingen E; Langen KJ
J Nucl Med; 2020 Apr; 61(4):505-511. PubMed ID: 31519802
[TBL] [Abstract][Full Text] [Related]
29. IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.
Ammendola S; Broggi G; Barresi V
Histol Histopathol; 2023 Jul; 38(7):739-753. PubMed ID: 36651583
[TBL] [Abstract][Full Text] [Related]
30.
Cicone F; Carideo L; Scaringi C; Arcella A; Giangaspero F; Scopinaro F; Minniti G
Ann Nucl Med; 2019 Apr; 33(4):295-302. PubMed ID: 30607877
[TBL] [Abstract][Full Text] [Related]
31. Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study.
Verburg N; Koopman T; Yaqub MM; Hoekstra OS; Lammertsma AA; Barkhof F; Pouwels PJW; Reijneveld JC; Heimans JJ; Rozemuller AJM; Bruynzeel AME; Lagerwaard F; Vandertop WP; Boellaard R; Wesseling P; de Witt Hamer PC
Neuro Oncol; 2020 Mar; 22(3):412-422. PubMed ID: 31550353
[TBL] [Abstract][Full Text] [Related]
32. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
[TBL] [Abstract][Full Text] [Related]
33. HIP1R and vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma.
Felix M; Friedel D; Jayavelu AK; Filipski K; Reinhardt A; Warnken U; Stichel D; Schrimpf D; Korshunov A; Wang Y; Kessler T; Etminan N; Unterberg A; Herold-Mende C; Heikaus L; Sahm F; Wick W; Harter PN; von Deimling A; Reuss DE
Neuro Oncol; 2022 Dec; 24(12):2121-2132. PubMed ID: 35511748
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with 18F-fluoromisonidazole PET.
Wang Y; Fushimi Y; Arakawa Y; Shimizu Y; Sano K; Sakata A; Nakajima S; Okuchi S; Hinoda T; Oshima S; Otani S; Ishimori T; Tanji M; Mineharu Y; Yoshida K; Nakamoto Y
Jpn J Radiol; 2023 Nov; 41(11):1255-1264. PubMed ID: 37219717
[TBL] [Abstract][Full Text] [Related]
35. Combining hyperintense FLAIR rim and radiological features in identifying IDH mutant 1p/19q non-codeleted lower-grade glioma.
Li M; Ren X; Chen X; Wang J; Shen S; Jiang H; Yang C; Zhao X; Zhu Q; Cui Y; Lin S
Eur Radiol; 2022 Jun; 32(6):3869-3879. PubMed ID: 35079884
[TBL] [Abstract][Full Text] [Related]
36. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
[TBL] [Abstract][Full Text] [Related]
37. Radiogenomics Provides Insights into Gliomas Demonstrating Single-Arm 1p or 19q Deletion.
Lasocki A; Buckland ME; Molinaro T; Xie J; Gaillard F
AJNR Am J Neuroradiol; 2023 Nov; 44(11):1270-1274. PubMed ID: 37884300
[TBL] [Abstract][Full Text] [Related]
38. Usefulness of positron emission tomography for differentiating gliomas according to the 2016 World Health Organization classification of tumors of the central nervous system.
Takei H; Shinoda J; Ikuta S; Maruyama T; Muragaki Y; Kawasaki T; Ikegame Y; Okada M; Ito T; Asano Y; Yokoyama K; Nakayama N; Yano H; Iwama T
J Neurosurg; 2019 Aug; 133(4):1010-1019. PubMed ID: 31419796
[TBL] [Abstract][Full Text] [Related]
39. Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in
Batchala PP; Muttikkal TJE; Donahue JH; Patrie JT; Schiff D; Fadul CE; Mrachek EK; Lopes MB; Jain R; Patel SH
AJNR Am J Neuroradiol; 2019 Mar; 40(3):426-432. PubMed ID: 30705071
[TBL] [Abstract][Full Text] [Related]
40. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology.
Ammendola S; Caldonazzi N; Simbolo M; Piredda ML; Brunelli M; Poliani PL; Pinna G; Sala F; Ghimenton C; Scarpa A; Barresi V
Virchows Arch; 2021 Nov; 479(5):987-996. PubMed ID: 34165590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
